Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer
2011-003502-24Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tivozanib, bevacizumab, fluorouracil, folinic acid and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Progression-free survival. Started Dec 2011; status: completed.
02
Drugs
tivozanibbevacizumabfluorouracilfolinic acidoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-003502-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003502-24.